ERBB2 and neoplasm: The combined use of the targeted monoclonal antibody trastuzumab in conjunction with paclitaxel (T-Trust regimen) in the presence of overexpression of the HER2-neu oncoprotein in tumor tissue made it possible to reduce the detection rate of targeted CTCs by 6.6%, but this decrease is not statistically significant (p > 0.05).